top of page


ANI Pharmaceuticals launches $560 million recommended offer to acquire Egetis Therapeutics
ANI Pharmaceuticals has launched a recommended cash offer valued at approximately $560 million for Swedish rare-disease specialist Egetis Therapeutics, seeking to add the approved MCT8-deficiency treatment Emcitate to its portfolio.

nuaxia
Nov 62 min read


FDA approves Emcitate as first treatment for MCT8 deficiency
The FDA has approved Emcitate as the first treatment for MCT8 deficiency, providing a therapy for the peripheral thyrotoxicosis associated with this ultra-rare genetic disorder.

nuaxia
Sep 291 min read
bottom of page